Parexel's COVID-19 expert content
-
Learn MoreThe Parexel Podcast | Episode 15: Pandemic preparedness: Investing in the future of infectious disease vaccine development
-
Learn MoreDrug Development for Rare Disease and Oncology During the COVID-19 Pandemic
-
Learn MoreHow COVID-19 Testing Demand Threw off Thermo Fisher’s Acquisition of Qiagen
About the Authors Aaron Dy, Ph.D. is a Senior Analyst in the Health Advances...
-
Learn MoreBiopharma R&D in the Post-COVID World
About the Authors Steven Chang, Ph.D. is a Senior Analyst in the Health...
-
Learn MoreeBook: Biopharma in the COVID-19 World
-
Learn MoreThe Special Approval Pathway (SAP) for COVID-19 related products in China
The regulatory pathway for COVID-19 drugs in China is governed by the Special Approval Program (SAP) which was introduced by National Medical Product Administration (NMPA) in 2005. SAP is...
-
Learn MoreNMPA Guidance on the Management of Clinical Trials during the COVID-19 from July 2020
Conducting clinical trials during the COVID-19 pandemic has produced many challenges globally. The initiation, conduct, implementation and completion of a trial during this time requires special...
-
Learn MoreAgainst All Odds: Can Covid-19 Usher in a New Era in International Public Health Cooperation?
Key Takeaways The COVID-19 pandemic has drawn attention to international efforts to promote...
-
Learn MoreThe New Pragmatism: Clinical Trials, Investment and Regulations Post-COVID-19
Once the COVID-19 pandemic passes or is contained, the world will look and work very differently. The biopharmaceutical industry is no exception. In this podcast, Peyton Howell, Parexel’s Chief...
-
Learn MoreDemystifying SARS-CoV-2 Testing for COVID-19 (Third Edition – Part 1: Updates and Trends)
Click here to download the full presentation. SummaryAs the world continues to battle...
-
View Now
An opportunity in a time of crisis: COVID-19 and the new pragmatism
-
Learn MoreFDA Expectations for Responding to Employees in Pharmaceutical Manufacturing Infected with COVID-19
Global manufacturers and regulators are facing new challenges during the SARS-CoV-2 pandemic to maintain supply chains, and avoid shortages, of drugs, biologics and medical devices. Numerous...
-
Learn MoreeBook: Digital Health and the Global Pandemic
-
View NowEMA Guidance: Management of Clinical Trials - What it means for Patients?
A lay summary for patients participating in clinical trials
-
Learn MoreUsing risk assessment decision tree models to maintain safety and data validity in clinical trials during COVID-19
During the COVID-19 pandemic, challenges to the conduct of clinical trials may arise, e.g. due to travel restrictions or quarantines, interruptions to supply chains, or when site personnel or...
-
Learn MorePutting the Pandemic in Plain Language
The COVID-19 pandemic has brought many negative feelings to the forefront of our everyday lives, including anxiety, fear and social division, but what if we explored the new positive relationships...
-
Learn MoreSARS-CoV-2 Landscape of Repurposed Drug Trials and Key Lessons for the Future
About the Authors Saakshi Chadha, PhD is a Senior Analyst in the Health...
-
Learn MoreCOVID-19: Digestive symptoms of the novel virus and implications for clinical trials
As the entire healthcare ecosystem grapples with the COVID-19 virus, more evidence surfaces every day of manifestations beyond fever, respiratory symptoms and fatigue. In fact, a recent...
-
Learn MoreNavigating new steps in how FDA is managing COVID-19 Products
-
Learn MoreBiosimilars in the time of COVID-19 and beyond
Introduction The recent COVID-19 pandemic has triggered a race for pharmaceutical companies to repurpose their commercialized drugs approved for other clinical indications to treat patients...
-
Loading More...
